Breaking News

Pfizer Predicts a Waning Pandemic

January 31, 2023 • 1:34 pm CST
Pfizer Inc. Jan. 31, 2023
(Precision Vaccinations News)

Pfizer Inc. today announced its 2022 year-end financial results reflecting the COVID-19 pandemic's diminishing impact on society. Excluding COVID-19 products, the Company continues to expect 7% to 9% operational revenue growth in 2023.

While 2022 revenues for the Comirnaty vaccine exceeded the previous year by 3% at $37.81 billion, the company expects this amount to decrease to $13.5 billion this year.

Today's data indicates a projected demand reduction of just 65 million vaccines, compared to 92 million in 2022.

And from its COVID-19 antiviral treatment known as Paxlovid, Pfizer expects a 58% reduction in 2023.

Dr. Albert Bourla, Chairman and Chief Executive Officer, stated in a related press release on January 31, 2023, "2022 was a record-breaking year for Pfizer, not only in terms of revenue and earnings per share, which were the highest in our long history, but more importantly, in terms of the percentage of patients who have a positive perception of Pfizer and the work we do."

"As proud as we are about what we have accomplished, our focus is always on what is next."

"As we turn to 2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we've ever had in such a short period."

"We believe that the combination of these expected near-term launches, additional pipeline products that could potentially come to market in the medium-term, and anticipated contributions from business development, has the potential to set the company up for continued robust growth through the rest of this decade and beyond."

Our Trust Standards: Medical Advisory Committee

Share